Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-08-26
2002-08-20
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S826000, C424S400000, C424S499000
Reexamination Certificate
active
06436902
ABSTRACT:
TECHNICAL FIELD
The present invention relates to compositions and methods for pulmonary administration of parathyroid hormone (parathormone, PTH) to mammalian hosts for the treatment of osteoporosis.
BACKGROUND ART
Human parathyroid hormone is an 84 amino acid protein (SEQ ID NO: 1) involved in calcium and phosphorus homeostasis and control of bone growth and density. Human PTH may be obtained through peptide synthesis or from genetically engineered yeast, bacterial or mammalian cell hosts. Human PTH is also commercially available from Bachem Inc., Bubendorf, Switzerland. Production of recombinant human parathyroid hormone is disclosed in EP-B0383751.
In mammals, the balance between bone formation, associated with the activity of osteoblasts, on one hand, and bone loss, associated with the activity of osteoclasts, on the other hand, is disturbed in several bone affecting diseases, such as osteoporosis. Parathyroid hormone has been shown to have a potential therapeutic role in osteoporosis. The anabolic actions of parathyroid hormone on bone are reviewed in Dempster et al. (1993) Endocrine Reviews, vol. 14, 690-709.
The N-terminal fragment of human PTH (PTH 1-34) was shown to have an anabolic effect on trabecular bone in involutional osteoporosis by Reeve et al. (1980) British Medical Journal, vol. 280, 1340-1344. However, the administration of a wild-type protein is to be preferred when possible, since this will ensure that all biological effects of the natural protein are exerted by the administered compound.
Polypeptide drugs such as PTH cannot be orally administered in effective doses, since they are rapidly degraded by enzymes in the gastrointestinal tract, and by the low pH in the stomach, before they can reach the bloodstream. Administration of PTH has generally been accomplished subcutaneously by injection. However, injection on a daily basis is inconvenient for the patient. Because of these disadvantages, there is a need for PTH in a form which is administrable other than by injection.
Pulmonary delivery of parathyroid hormone and N-terminal fragments thereof to rats is disclosed in WO 94/07514. When the N-terminal fragment consisting of amino acids 1-34 (PTH34) was administered to rats intratracheally (IT), the serum profile exhibited a peak after 15 minutes with activity diminishing rapidly thereafter. In contrast, the serum profile after IT administration of full-length PTH (ME84) exhibited a plateau which did not diminish significantly during the 90 minutes of the experiment. Since it is known that PTH is most effectively delivered to a patient in pulsatile fashion, i.e. serum concentrations should rise rapidly after administration and fall rapidly after a peak has been reached, it is concluded in the document WO 94/07514 that N-terminal fragments of PTH is preferred over the full-length protein for pulmonary delivery.
SUMMARY OF THE INVENTIVE CONCEPT
According to the present invention it has been shown that a pulsative plasma profile is obtained when full-length PTH as a dry powder aerosol is inhaled via an endotracheal tube by dogs. It has thus surprisingly been shown that pulmonary administration of full-length PTH, contrary to the conclusions expressed in the published patent application WO 94/07514, will be effective for stimulating bone formation and for the treatment of osteoporosis.
REFERENCES:
patent: 2992645 (1961-07-01), Fowler
patent: 3014844 (1961-12-01), Thiel et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4690952 (1987-09-01), Kagatani et al.
patent: 4788221 (1988-11-01), Kagatani et al.
patent: 4847298 (1989-07-01), Alexander et al.
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4900730 (1990-02-01), Miyauchi
patent: 4907583 (1990-03-01), Wetterlin et al.
patent: 4963367 (1990-10-01), Ecanow
patent: 4994439 (1991-02-01), Longenecker et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5011678 (1991-04-01), Wang et al.
patent: 5118494 (1992-06-01), Schultz et al.
patent: 5122127 (1992-06-01), Stanley
patent: 5122376 (1992-06-01), Aliverti et al.
patent: 5179079 (1993-01-01), Hansen et al.
patent: 5200393 (1993-04-01), Weiner
patent: 5202129 (1993-04-01), Samajima et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5320094 (1994-06-01), Laube et al.
patent: 5341800 (1994-08-01), Clark et al.
patent: 5348730 (1994-09-01), Greenleaf et al.
patent: 5349947 (1994-09-01), Newhouse et al.
patent: 5354562 (1994-10-01), Platz et al.
patent: 5364838 (1994-11-01), Rubsamen
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5419315 (1995-05-01), Rubsamen
patent: 5437271 (1995-08-01), Hodson et al.
patent: 5451569 (1995-09-01), Wong et al.
patent: 5482706 (1996-01-01), Igari et al.
patent: 5506203 (1996-04-01), Backstrom et al.
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5518998 (1996-05-01), Backstrom et al.
patent: 5607915 (1997-03-01), Patton
patent: 5661130 (1997-08-01), Meezan et al.
patent: 5707644 (1998-01-01), Illum
patent: 5730969 (1998-03-01), Hora et al.
patent: 5747445 (1998-05-01), Backstrom et al.
patent: 5997848 (1999-12-01), Patton et al.
patent: 6051256 (2000-04-01), Platz et al.
patent: 261 096 (1988-10-01), None
patent: 0 023 359 (1980-07-01), None
patent: 312052 (1987-10-01), None
patent: 364235 (1988-04-01), None
patent: 0 360 340 (1990-03-01), None
patent: 837465 (1960-06-01), None
patent: 1242211 (1971-08-01), None
patent: 1520247 (1978-08-01), None
patent: 1569611 (1980-06-01), None
patent: 1117825 (1987-02-01), None
patent: 632932 (1988-07-01), None
patent: 4041421 (1990-06-01), None
patent: 4149126 (1992-05-01), None
patent: 88/09163 (1988-12-01), None
patent: WO 91/16038 (1991-10-01), None
patent: WO 91/16882 (1991-11-01), None
patent: WO 92/04069 (1992-03-01), None
patent: WO 92/06704 (1992-04-01), None
patent: 9407514 (1994-04-01), None
patent: WO 95/00151 (1995-01-01), None
patent: WO 97/10850 (1997-03-01), None
Li et al., “Effect of a . . . ,” Eur. J. Pharm. Biopharm., 39:216-221, 1993.
Byron et al., “Drug Delivery via the Respiratory . . . ,” Journal of Aerosol Medicine, 7:49-75, 1994.
Nagano et al., “New Method of Insulin . . . ,” Jikeikai Med. J., 32:503-506, 1985.
Elliott et al., “Parenteral absorption of insulin . . . ,” Aust. Paediatr. J., 23:293-297, 1987.
Sakr., “A new approach for insulin . . . ,” International Journal of Pharmaceutics, 86:1-7, 1992.
Liu et al., “Pulmonary Delivery of Free . . . ,” Pharmaceutical Research, 10:228-232, 1993.
Jaegfeldt et al., “Particle size distribution from different modifications . . . ,” Proceedings of an international workshop on a new inhaler, May 21-22, 1987, London, U.K., pp. 90-99.
Li et al., “Effect of a Conjugated Bile Salt on the Pulmonary . . . ,” Eur. J. Pharm. Biopharm, vol. 39, pp. 216-221, 1993.
Okumura et al., “Intratracheal delivery of insulin Absorption . . . ,” International Journal of Pharmaceutics, vol. 88, pp. 63-73, 1992.
Wetterlin, “Turbuhaler: A New Powder Inhaler for Administration . . . ,” Pharmaceutical Research, vol. 5, pp. 506-508, 1988.
Yamamoto et al., “Absorption Enhancement of Intrapulmonary Administered Insulin . . . ,” J. Pharm. Pharmacol, vol. 46, pp. 14-18, 1994.
“Bioavailability of pulmonary delivered peptides and proteins: alpha-interferon, calcitonins and parathyroid hormones”, J. Control. Release (Netherlands), (1994), 28/1-3, pp. 79-85.
Almer et al.,Diabetes Res. and Clin. Pract, 5:S163 (1988).
Bjork, Acta Univ. Uppsala, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, 103 (1993).
Laube et al., “Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic Patients”,JAMA, 269(16):2106-2109 (1993).
Lee et al., “Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio”,J. Pharm. Sci., 80(8):725-729, (1991).
Lee et al., “Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption”,Critical Rev. Therapeut. Drug Carrier Systems, 8(2):91-192 (1991).
Komada et al., “Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung”,J
Bäckström Kjell
Dahlbäck Magnus
Edman Peter
Johansson Ann
Wallmark Björn
AstraZeneca AB
Borin Michael
Fish & Richardson P.C.
LandOfFree
Therapeutic preparations for inhalation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic preparations for inhalation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic preparations for inhalation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2892368